

Financial news for TGTX dated on 2020-05-29: TG Therapeutics Announces Final Results Of Leukemia Trial At ASCO

Financial news for TGTX dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for TGTX dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TGTX dated on 2020-05-20: Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.

Financial news for TGTX dated on 2020-05-18: TG Therapeutics shares are trading higher after B. Riley FBR maintained its Buy rating on the stock and raised its price target from \$29 to \$37 per share.

Financial news for TGTX dated on 2020-05-18: B. Riley FBR Maintains Buy on TG Therapeutics, Raises Price Target to \$37

Financial news for TGTX dated on 2020-05-15: The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO

Financial news for TGTX dated on 2020-05-15: TG Therapeutics shares are trading lower after the company announced a common stock offering of 8.5 million shares at \$18 per share.

Financial news for TGTX dated on 2020-05-15: TG Therapeutics Prices Upsized 8.5M Share Public Offering of Common Stock @\$18/Share

Financial news for TGTX dated on 2020-05-15: 5 Stocks To Watch For May 15, 2020

Financial news for TGTX dated on 2020-05-14: TG Therapeutics Announces Proposed Public Offering of 6M Shares Of Common Stock

Financial news for TGTX dated on 2020-05-14: TG Therapeutics Highlights Data Presentations At ASCO May 29-31, European Hematology Association Congress Jun. 11-14

Financial news for TGTX dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for TGTX dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TGTX dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for TGTX dated on 2020-05-11: TG Therapeutics Q1 EPS \$(0.480) Down From \$(0.430) YoY, Sales \$38.000K, Same YoY

Financial news for TGTX dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for TGTX dated on 2020-05-07: 66 Biggest Movers From Yesterday

Financial news for TGTX dated on 2020-05-06: 58 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TGTX dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for TGTX dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for TGTX dated on 2020-05-06: B. Riley FBR Maintains Buy on TG Therapeutics, Raises Price Target to \$29

Financial news for TGTX dated on 2020-05-06: 19 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for TGTX dated on 2020-05-06: TG Therapeutics shares are trading higher after the company reported it has raised approximately \$60 million in gross proceeds through its at-the-market offering.

Financial news for TGTX dated on 2020-05-06: TG Therapeutics Reports Raised \$60M In Gross Proceeds From At-The-Market Offering

Financial news for TGTX dated on 2020-05-06: Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to \$35

Financial news for TGTX dated on 2020-05-06: 70 Biggest Movers From Yesterday

Financial news for TGTX dated on 2020-05-05: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TGTX dated on 2020-05-05: HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to \$32

Financial news for TGTX dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TGTX dated on 2020-05-05: TG Therapeutics shares are trading higher after the company announced the results from its UNITY-CLL Phase 3 study for patients with Chronic Lymphocytic Leukemia met its primary endpoint.

Financial news for TGTX dated on 2020-05-05: TG Therapeutics Announces Topline Results From UNITY-CLL Phase 3 Study Evaluating Combination Of Umbralisib And Ublituximab For Patients With Chronic Lymphocytic Leukemia; Trial Met Primary Endpoint

Financial news for TGTX dated on 2020-05-01: TG Therapeutics Highlights Publication Of Ublituximab Phase 2 Trials Results In Multiple Sclerosis Journal: Says Was Generally Well Tolerated

Financial news for TGTX dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for TGTX dated on 2020-03-16: Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for TGTX dated on 2020-03-05: TG Therapeutics Reports Orphan Drug Designation For Umbralisib For Treatment Of Follicular Lymphoma

Financial news for TGTX dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for TGTX dated on 2020-03-03: TG Therapeutics Q4 EPS \$(0.44) Up From \$(0.68) YoY, Sales \$38K, Same YoY

Financial news for TGTX dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for TGTX dated on 2020-02-26: 24 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for TGTX dated on 2020-02-26: 44 Stocks Moving in Wednesday's Pre-Market Session

Financial news for TGTX dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for TGTX dated on 2020-02-18: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TGTX dated on 2020-02-18: 35 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for TGTX dated on 2020-02-14: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for TGTX dated on 2020-02-14: 9 Biotechnology Stocks Moving In Friday's Pre-Market Session

Financial news for TGTX dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TGTX dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for TGTX dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for TGTX dated on 2020-02-06: Stocks That Hit 52-Week Highs On Thursday

Financial news for TGTX dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off

Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for TGTX dated on 2020-02-04: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TGTX dated on 2020-01-23: TG Therapeutics Option Alert: Feb 21 \$19 Calls Sweep (2) above Ask!: 2189 @ \$0.276 vs 3922 OI; Earnings 2/28 Before Open [est] Ref=\$13.43

Financial news for TGTX dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for TGTX dated on 2020-01-17: H.C. Wainwright Maintains Buy on TG Therapeutics, Raises Price Target to \$24

Financial news for TGTX dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for TGTX dated on 2020-01-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for TGTX dated on 2020-01-16: TG Therapeutics Reports Initiation Of Rolling Submission Of New Drug Application To FDA For Umbralisib As Treatment For Patients Previously Treated With Marginal Zone Lymphoma Or Follicular Lymphoma

Financial news for TGTX dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for TGTX dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for TGTX dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for TGTX dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for TGTX dated on 2020-01-10: The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

Financial news for TGTX dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for TGTX dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for TGTX dated on 2020-01-08: The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results

Financial news for TGTX dated on 2019-12-27: Stocks That Hit 52-Week Highs On Friday

Financial news for TGTX dated on 2019-12-27: 31 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for TGTX dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for TGTX dated on 2019-12-26: The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

Financial news for TGTX dated on 2019-12-24: The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

Financial news for TGTX dated on 2019-12-23: TG Therapeutics Announces \$50M Registered Direct Offering at \$9.20/Share

Financial news for TGTX dated on 2019-12-16: 58 Biggest Movers From Friday

Financial news for TGTX dated on 2019-12-13: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for TGTX dated on 2019-12-13: Stocks That Hit 52-Week Highs On Friday

Financial news for TGTX dated on 2019-12-13: TG Therapeutics shares are trading higher on seemingly no company-specific news.

Financial news for TGTX dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for TGTX dated on 2019-12-10: Stocks That Hit 52-Week Highs On Tuesday

Financial news for TGTX dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for TGTX dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for TGTX dated on 2019-12-09: 5 Stocks Moving On ASH Presentations

Financial news for TGTX dated on 2019-12-09: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for TGTX dated on 2019-12-09: 38 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for TGTX dated on 2019-12-09: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for TGTX dated on 2019-12-09: TG Therapeutics shares are trading higher after the company announced a 100% overall response rate in its phase 1/2 study of ublituximab.

Financial news for TGTX dated on 2019-12-08: TG Therapeutics Announces 100% Overall Response Rate in Relapsed/Refractory CLL Patients Treated With U2 (Umbralisib + Ublituximab) Plus Venetoclax at Cycle 7 (N=13) at ASH 2019

Financial news for TGTX dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for TGTX dated on 2019-11-29: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for TGTX dated on 2019-11-29: TG Therapeutics shares are trading higher. Not seeing any news to justify the price action.

Financial news for TGTX dated on 2019-11-14: Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Lowers Price Target to \$19

Financial news for TGTX dated on 2019-11-12: TG Therapeutics Q3 EPS \$(0.69) May Not Compare To \$(0.34) Estimate

Financial news for TGTX dated on 2019-10-29: 46 Biggest Movers From Yesterday

Financial news for TGTX dated on 2019-10-28: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for TGTX dated on 2019-10-28: TG Therapeutics shares are trading higher after the company announced Phase 2b pivotal trial met its primary endpoint.

Financial news for TGTX dated on 2019-10-28: 28 Stocks Moving in Monday's Pre-Market Session

Financial news for TGTX dated on 2019-10-28: TG Therapeutics' Phase 2b Pivotal Trial Met its Primary Endpoint

Financial news for TGTX dated on 2019-10-24: TG Therapeutics Announces Final Long-Term Results From Phase 3 GENUINE Study Of Ublituximab In Combination With Ibrutinib In Patients With High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia

Financial news for TGTX dated on 2019-10-16: TG Therapeutics Option Alert: Nov 15 \$5 Calls Sweep (2) near the Ask: 931 @ \$0.676 vs 233 OI; Earnings 11/8 Before Open [est] Ref=\$5.365

Financial news for TGTX dated on 2019-10-01: Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.

Financial news for TGTX dated on 2019-09-30: TG Therapeutics Announces Publication of Clinical Data From the Phase I/Ib Combination Trial of Ublituximab and Umbralisib in a Medical Journal

Financial news for TGTX dated on 2019-09-30: 52 Biggest Movers From Friday

Financial news for TGTX dated on 2019-09-27: 34 Stocks Moving In Friday's Mid-Day Session

Financial news for TGTX dated on 2019-09-27: TG Therapeutics shares are trading

higher on seemingly no company-specific news.

Financial news for TGTX dated on 2019-09-12: The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study

Financial news for TGTX dated on 2019-09-12: TG Therapeutics Highlights Presentation Of Data For Ublituximab At European Committee for Treatment and Research in Multiple Sclerosis

Financial news for TGTX dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for TGTX dated on 2019-09-05: TG Therapeutics Files To Withdraw Registration Statement On Form S-3

Financial news for TGTX dated on 2019-08-12: Large Option Trader Sells TG Therapeutics Calls After Big Run

Financial news for TGTX dated on 2019-08-09: TG Therapeutics Q2 EPS \$(0.42) Misses \$(0.41) Estimate, Sales \$38K Beat \$20K Estimate

Financial news for TGTX dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for TGTX dated on 2019-08-02: 29 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for TGTX dated on 2019-07-02: TG Therapeutics Highlights Presentation Of Long-Term Follow-Up Data From Phase 2 Trial Of Ublituximab In Patients With Multiple Sclerosis During An Oral Session At 5th Congress Of European Academy Of Neurology

Financial news for TGTX dated on 2019-06-28: 62 Biggest Movers From Yesterday

Financial news for TGTX dated on 2019-06-20: TG Therapeutics Highlights Presentation Of Data At 15th International Conference On Malignant Lymphoma

Financial news for TGTX dated on 2019-06-17: TG Therapeutics Presents Preclinical Data for TG-1801 at the 24th European Hematology Association Annual Congress

Financial news for TGTX dated on 2019-06-11: TG Therapeutics Confirms Registration Path For Umbralisib In Marginal Zone Lymphoma Following FDA Meeting

Financial news for TGTX dated on 2019-06-04: TG Therapeutics Reports Interim Data From UNITY-NHL Phase 2b Trial On Umbralisib Monotherapy In Patients with Marginal Zone Lymphoma Showed Overall Response Rate Of 52%, Complete Response Of 19%, Was Well Tolerated

Financial news for TGTX dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for TGTX dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for TGTX dated on 2019-05-10: TG Therapeutics Q4 EPS \$(0.43), Inline, Sales \$38K Beat \$20K Estimate

Financial news for TGTX dated on 2019-05-07: UPDATE: TG Therapeutics Says 'Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks'

Financial news for TGTX dated on 2019-05-07: TG Therapeutics Reports Long-Term Follow-Up Data From Phase 2 Trial Of Ublituximab In Patients Multiple Sclerosis at the American Academy of Neurology Annual Meeting

Financial news for TGTX dated on 2019-05-03: TG Therapeutics Option Alert: Jun 21 \$11 Calls Sweep (23) near the Ask: 844 @ \$0.3 vs 301 OI; Earnings 5/8 Before Open [est] Ref=\$8.055

Financial news for TGTX dated on 2019-04-17: Betaville Article Discusses Trader Speculation Of Jazz Pharmaceuticals Interest In Acquiring TG Therapeutics

Financial news for TGTX dated on 2019-04-17: TG Therapeutics Option Alert: Thu \$8 Calls Sweep (6) near the Ask: 500 @ \$0.5 vs 10734 OI; Earnings 5/7 Before Open [est] Ref=\$8.46

Financial news for TGTX dated on 2019-04-17: TG Therapeutics Option Alert: May 17 \$8

Calls Sweep (31) near the Ask: 568 @ \$0.801 vs 1731 OI; Earnings 5/7 Before Open
[est] Ref=\$7.92

Financial news for TGTX dated on 2019-04-15: TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the US FDA for the Treatment of Marginal Zone Lymphoma

Financial news for TGTX dated on 2019-04-12: TG Therapeutics Shares Volatile, Up 2.2%; Hearing Co. Receive Orphan Drug Status For Its Umbralisib

Financial news for TGTX dated on 2019-04-11: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for TGTX dated on 2019-04-01: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for TGTX dated on 2019-04-01: TG Therapeutics shares are trading higher after the company reported positive interim trial data evaluating Umbralisib.

Financial news for TGTX dated on 2019-04-01: Benzinga Pro's Top 8 Most-Searched Tickers For Morning Of Monday, Apr. 1, 2019

Financial news for TGTX dated on 2019-04-01: TG Therapeutics Highlights Presentation Of Interim Data From UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy In Patients With Marginal Zone Lymphoma At 2019 AACR Annual Meeting

Financial news for TGTX dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for TGTX dated on 2019-03-29: TGTX shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.

Financial news for TGTX dated on 2019-03-29: Cantor Fitzgerald Initiates Coverage On TG Therapeutics with Overweight Rating

Financial news for TGTX dated on 2019-03-08: TG Therapeutics Announces Outcome From Data Safety Monitoring Board Reviews Of UNITY-CLL And UNITY-NHL Clinical Trials; Board Identified No Safety Concerns And Recommended Trial Continue Without Modification

Financial news for TGTX dated on 2019-03-05: TG Therapeutics Filing Shows Registration For 4.1M Share Common Stock Offering

Financial news for TGTX dated on 2019-03-01: TG Therapeutics Reports ~\$85M In Equity, Debt Financings

Financial news for TGTX dated on 2019-03-01: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 1, 2019

Financial news for TGTX dated on 2019-03-01: The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis

Financial news for TGTX dated on 2019-03-01: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for TGTX dated on 2019-03-01: TG Therapeutics Reports Will Present Final Phase 2 Data For Multiple Sclerosis Treatment At ACTRIMS Meeting

Financial news for TGTX dated on 2019-03-01: 75 Biggest Movers From Yesterday

Financial news for TGTX dated on 2019-02-28: TG Therapeutics Announces Common Stock Offering, Size Not Disclosed; Co. Also Enters Into \$60M Venture Debt Financing Agreement

Financial news for TGTX dated on 2019-02-28: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for TGTX dated on 2019-02-28: TG Therapeutics shares are trading higher after the company announced its UNITY-NHL phase 2b pivotal trial evaluating umbralisib met the primary endpoint of overall response rate in patients with relapsed/refractory marginal zone lymphoma.

Financial news for TGTX dated on 2019-02-28: 34 Stocks Moving In Thursday's Pre-Market Session

Financial news for TGTX dated on 2019-02-28: TG Therapeutics Announces UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Met Primary Endpoint Of Overall Response Rate In Patients With Relapsed/Refractory Marginal Zone Lymphoma

Financial news for TGTX dated on 2019-02-26: TG Therapeutics Reports Initiation Of

Phase I First-In-Human Trial Of TG-1801 In Patients With Relapsed, Refractory B-Cell Lymphoma

Financial news for TGTX dated on 2019-01-30: TG Therapeutics Highlights Publication Of Data From Phase I Triple Therapy Combo Trial O'f Ublituximab, Umbralisib, Ibrutinib In 'The Lancet Haematology'

Financial news for TGTX dated on 2019-01-22: TG Therapeutics Receives Breakthrough Therapy Designation from the FDA for Umbralisib for the Treatment of Marginal Zone Lymphoma

Financial news for TGTX dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for TGTX dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for TGTX dated on 2018-12-04: TG Therapeutics Offers Follow-Up Data From Triple Combo Of Ublituximab, Umbralisib, Bendamustine In Patients With DLBCL, FL At ASH

Financial news for TGTX dated on 2018-11-19: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for TGTX dated on 2018-11-13: TG Therapeutics Announces Phase I Study Of Novel BTK inhibitor, TG-1701, In Patients With Relapsed Or Refractory B-cell Malignancies Is Open For Enrollment

Financial news for TGTX dated on 2018-11-09: TG Therapeutics Q3 EPS \$(0.43) Beats \$(0.54) Estimate, Sales \$38K Beat \$30K Estimate

Financial news for TGTX dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for TGTX dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for TGTX dated on 2018-10-22: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for TGTX dated on 2018-10-11: The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Financial news for TGTX dated on 2018-10-08: The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

Financial news for TGTX dated on 2018-10-05: 5 Stocks To Have On Your Radar Next Week

Financial news for TGTX dated on 2018-09-27: Stocks Which Set New 52-Week Low Yesterday, September 26th

Financial news for TGTX dated on 2018-09-26: Stocks Which Set New 52-Week Low Yesterday, September 25th

Financial news for TGTX dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for TGTX dated on 2018-09-26: 51 Biggest Movers From Yesterday

Financial news for TGTX dated on 2018-09-25: Mid-Afternoon Market Update: Neogen Falls After Q1 Results; Jaguar Health Shares Surge

Financial news for TGTX dated on 2018-09-25: 41 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TGTX dated on 2018-09-25: Mid-Day Market Update: Sonic Gains Following Acquisition News; Opiant Pharmaceuticals Shares Plummet

Financial news for TGTX dated on 2018-09-25: TG Therapeutics shares are down 34.3% after an Independent Data Safety Monitoring Board advised the company that data in the UNITY-CLL trial were not mature and an overall response rate could not be completed as expected.

Financial news for TGTX dated on 2018-09-25: Raymond James Downgrades TG Therapeutics to Outperform, Lowers Price Target to \$12

Financial news for TGTX dated on 2018-09-25: Mid-Morning Market Update: Markets Mostly Flat; FactSet Research Misses Q4 Estimates

Financial news for TGTX dated on 2018-09-25: Hearing TG Therapeutics Downgraded at Raymond James, Unconfirmed

Financial news for TGTX dated on 2018-09-25: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TGTX dated on 2018-09-25: TG Therapeutics Shares Resume Trade, Down 44%

Financial news for TGTX dated on 2018-09-25: TG Therapeutics Shares To Resume Trade At 7:30 a.m. EDT

Financial news for TGTX dated on 2018-09-25: TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial; Independent Data Safety Monitoring Board Advised Co. That Interim Analysis Of Overall Response Rate Could Not Be Conducted, As Data Were Not Sufficiently Mature To Conduct Analysis

Financial news for TGTX dated on 2018-09-25: TG Therapeutics, Reata Pharma Shares Halted News Pending

Financial news for TGTX dated on 2018-09-18: 50 Biggest Movers From Yesterday

Financial news for TGTX dated on 2018-09-17: 'Excellent \$TGTX thread here. You've been warned.'-STAT's Adam Feuerstein Tweets

Financial news for TGTX dated on 2018-08-26: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results

Financial news for TGTX dated on 2018-08-07: TG Therapeutics Q2 EPS \$(0.59) Misses \$(0.53) Estimate, Sales \$38K Beat \$30K Estimate

Financial news for TGTX dated on 2018-08-07: TG Therapeutics Reports Completed Target Enrollment In ULTIMATE Phase 3 Trials In Multiple Sclerosis

Financial news for TGTX dated on 2018-07-20: 32 Stocks Moving In Friday's Pre-Market Session

Financial news for TGTX dated on 2018-06-18: TG Therapeutics Announces Updated Results From PHase 2 Study Of ublituximab In Patients With MS

Financial news for TGTX dated on 2018-06-18: TG Therapeutics Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy

Financial news for TGTX dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for TGTX dated on 2018-05-08: TG Therapeutics Q1 EPS \$(0.59) Misses \$(0.44) Estimate, Sales \$38K Beat \$30K Estimate

Financial news for TGTX dated on 2018-04-24: TG Therapeutics Offers Updated Results From Ongoing Phase 2 Study Of TG-1101 In Patients With MS: 'Data on now up to 48 patients through 24 weeks confirms previously reported positive results'

Financial news for TGTX dated on 2018-03-13: TG Therapeutics Option Alert: May 18 \$15 Puts Sweep (24) at the Bid: 770 @ \$1.301 vs 331 OI; Earnings 5/4 Before Open [est] Ref=\$16.575

Financial news for TGTX dated on 2018-03-08: TG Therapeutics Says Believes It Has Sufficient Cash To Operate Through Mid-2019

Financial news for TGTX dated on 2018-03-08: TG Therapeutics Reports Q4 EPS \$(0.46) vs \$(0.44) Est., License Sales \$38.095K vs \$30K Est.

Financial news for TGTX dated on 2018-03-06: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TGTX dated on 2018-02-28: Jim Cramer Gives His Opinion On ConocoPhillips, Texas Instruments And More

Financial news for TGTX dated on 2018-02-21: TG Therapeutics, Inc. Reports Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology

Financial news for TGTX dated on 2018-02-05: Seeing Notable Block Trade In TG Therapeutics Of 1.6M Shares At \$12.20/Share

Financial news for TGTX dated on 2018-02-02: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for TGTX dated on 2018-02-02: TG Therapeutics Presented Results from Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018

Financial news for TGTX dated on 2018-02-02: TG Therapeutics Says TG-1101 Well Tolerated in Patients with MS

Financial news for TGTX dated on 2018-01-29: TG Therapeutics Option Alert: Mar 16 \$14 Calls Sweep (18) at the Ask: 500 @ \$0.801 vs 91 OI; Earnings 3/9 Before Open [est] Ref=\$12.35

Financial news for TGTX dated on 2018-01-12: 46 Biggest Movers From Yesterday

Financial news for TGTX dated on 2018-01-08: TG Therapeutics, Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program, US IND Filing Expected in the First Half of 2018

Financial news for TGTX dated on 2017-12-27: Seeing Notable Block Trade In TG Therapeutics; 1.8M Shares At \$8.375

Financial news for TGTX dated on 2017-12-01: B. Riley Reinstates Buy on TG Therapeutics, Announces \$21.50

Financial news for TGTX dated on 2017-11-14: Benzinga's Top Upgrades, Downgrades For November 14, 2017

Financial news for TGTX dated on 2017-11-14: H.C. Wainwright Assumes TG Therapeutics at Buy, Announces price target \$33.00

Financial news for TGTX dated on 2017-11-08: TG Therapeutics Reports Q3 EPS \$(0.48) vs \$(0.43) Est., Sales \$38K vs \$30K Est.

Financial news for TGTX dated on 2017-11-01: TG Therapeutics Option Alert: May 18 \$12 Calls Sweep (2) at the Bid: 500 @ \$1.051 vs 2030 OI; Ref=\$7.90

Financial news for TGTX dated on 2017-10-27: UPDATE: TG Therapeutics Says 'TG-1101 was well tolerated across all patients including those receiving 1 hour infusions of the Phase 3 450mg dose'

Financial news for TGTX dated on 2017-10-27: TG Therapeutics Reports Added Updated Results From Ongoing Phase 2 Study Of TG-1101 In Patients With MS: '99% median B-cell depletion was observed at week 4 and maintained at week 24'

Financial news for TGTX dated on 2017-10-26: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for TGTX dated on 2017-10-26: TG Therapeutics Rise 8% Premarket After Announcing Positive Results from Ongoing Phase 2 Study of TG-1101 in Patients with MS

Financial news for TGTX dated on 2017-10-20: Benzinga's Option Alert Recap From October 20

Financial news for TGTX dated on 2017-10-20: TG Therapeutics Option Alert: Feb 16 \$12 Calls at the Bid: 1000 @ \$0.5 vs 429 OI; Ref=\$7.6

Financial news for TGTX dated on 2017-10-18: TG Therapeutics Shares Spike Higher Off Afternoon Lows As Hearing SunTrust Recommending Investors Buy Stock 'Aggressively'

Financial news for TGTX dated on 2017-10-17: 35 Biggest Movers From Yesterday

Financial news for TGTX dated on 2017-10-16: Mid-Afternoon Market Update: Sears Tumbles After Bruce Berkowitz Resigns From Board; Exelixis Shares Surge

Financial news for TGTX dated on 2017-10-16: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for TGTX dated on 2017-10-16: Mid-Day Market Update: TransEnterix Climbs Following FDA Clearance Of Senhance Surgical Robot; TG Therapeutics Shares Decline

Financial news for TGTX dated on 2017-10-16: Mid-Morning Market Update: Markets Open Higher; Charles Schwab Earnings Top Views

Financial news for TGTX dated on 2017-10-16: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for TGTX dated on 2017-10-16: TG Therapeutics Says The FDA Stated GENUINE 3 Results Will Cause an Issue for Getting Accelerated Approval

Financial news for TGTX dated on 2017-10-16: TG Therapeutics Says FDA Confirmed That Accelerated Approval Based On Overall Response Rate Would Be A Review Issue, Also Discussed Potential Use Of Progression Free Survival From GENUINE Trial To Support Full Approval of TG-1101

Financial news for TGTX dated on 2017-10-13: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for TGTX dated on 2017-10-12: Benzinga's Option Alert Recap From October 12

Financial news for TGTX dated on 2017-10-12: TG Therapeutics Option Alert: May 18 \$18 Calls at the Bid: 500 @ \$1.051 vs 0 OI; Ref=\$11.35

Financial news for TGTX dated on 2017-10-05: TG Therapeutics Reports Advancement Of Anti-PD-L1 Monoclonal Antibody Into Clinical Development

Financial news for TGTX dated on 2017-09-29: TG Therapeutics Reports TGR-1202 Selected For Grant From National Multiple Sclerosis Society To Support Development Of Candidate As Oral B-cell Targeted Treatment Option In Progressive MS

Financial news for TGTX dated on 2017-08-24: Watch These 8 Huge Call Purchases In Thursday Trade

Financial news for TGTX dated on 2017-08-23: TG Therapeutics Option Alert: Jan 19 \$18 Calls Sweep (7) at the Ask: 1000 @ \$0.899 vs 0 OI; Ref=\$11.45

Financial news for TGTX dated on 2017-08-10: UPDATE: TG Says 'As set forth in the protocol, single agent TGR-1202 arm will be replaced with the triple combination of TG-1101, TGR-1202 and bendamustine'

Financial news for TGTX dated on 2017-08-10: UPDATE: TG Therapeutics Says DSMB 'recommends continued enrollment in the TGR-1202 + TG-1101 arm and no further enrollment into the single agent TGR-1202 arm'

Financial news for TGTX dated on 2017-08-10: TG Therapeutics Reports Successful Outcome From First Pre-Planned Interim Analysis By Independent DSMB Of DLBCL Cohort In UNITY-NHLPhase 2b Trial

Financial news for TGTX dated on 2017-08-09: TG Therapeutics Reports Q2 EPS \$(0.45) vs \$(0.43) Est., Sales \$38.095K vs \$40K Est.

Financial news for TGTX dated on 2017-08-01: TG Therapeutics Announces Special Protocol Assessment Agreement with the FDA for a Phase 3 Program of TG-1101 For Patients with Multiple Sclerosis

Financial news for TGTX dated on 2017-06-26: TG Therapeutics Gives Update on Phase 2 Study of TG-1101

Financial news for TGTX dated on 2017-06-23: European Hematology Association (EHA) Congress 2017 Continues Today, Bellicum Pharma Expected To Present

Financial news for TGTX dated on 2017-06-22: European Hematology Association (EHA) Congress 2017 Begins Today, Day 1 of 4

Financial news for TGTX dated on 2017-06-16: TG Therapeutics Recaps Positive Data from Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at #ICML2017

Financial news for TGTX dated on 2017-06-15: TG Therapeutics Announces Follow-Up Data from Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at #ICML2017

Financial news for TGTX dated on 2017-06-14: TG Therapeutics Announces Follow-Up Data For TGR-1202, Well-Tolerated

Financial news for TGTX dated on 2017-06-14: Watch These 4 Huge Call Purchases In Wednesday Trade

Financial news for TGTX dated on 2017-06-13: Option Alert: TG Therapeutics Jun 12.0 Calls Sweep: 500 @ ASK \$0.15: 596 traded vs 2152 OI: Earnings 8/7 Before Open (est) \$11.02 Ref

Financial news for TGTX dated on 2017-06-05: TG Therapeutics Offers Follow-Up Data from Chemo-Free Triple Combo of TG-1101, TGR-1202, Ibrutinib: '100% ORR (19 of 19) observed in patients with CLL/SLL, including 32% CR rate'

Financial news for TGTX dated on 2017-06-05: 25 Stocks Moving In Monday's Pre-Market

Session

Financial news for TGTX dated on 2017-06-05: TG Therapeutics +8.3% Premarket @\$15.00 on Light Trading; Said Phase 3 GENUINE Trial Met Primary Endpoint with TG-1101 + Ibrutinib Increasing Overall Response Rate by >70% vs Ibrutinib Alone

Financial news for TGTX dated on 2017-06-03: UPDATE: TG Therapeutics Says Study Met Primary Endpoint with TG-1101 + Ibrutinib Increasing Overall Response Rate by >70% vs Ibrutinib Alone #ASCO17

Financial news for TGTX dated on 2017-06-03: TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia #ASCO17

Financial news for TGTX dated on 2017-05-26: TG Therapeutics Files For \$300M Mixed Shelf Offering

Financial news for TGTX dated on 2017-05-23: TG Therapeutics Reports Outcome from Pre-Planned Interim Analysis by Independent DSMB for UNITY-CLL Phase 3 Trial, Says Contribution of single Agents in Combo Regimen Successfully Established

Financial news for TGTX dated on 2017-05-05: TG Therapeutics Reports Q1 EPS \$(0.52) vs \$(0.38) Est.

Financial news for TGTX dated on 2017-04-28: TG Therapeutics Reports Prelim Results From Ongoing Phase 2 TG-1101 Study, Was Well Tolerated, Met Primary Endpoint

Financial news for TGTX dated on 2017-04-25: Potential FDA Controversy Brewing For TG Therapeutics?

Financial news for TGTX dated on 2017-04-25: Jefferies Initiates Coverage On TG Therapeutics with Buy Rating, Announces \$23.00 Price Target

Financial news for TGTX dated on 2017-04-21: Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics

Financial news for TGTX dated on 2017-04-04: TG Therapeutics Offers Preclinical Data for Anti-PD-L1 Monoclonal Antibody, Says First In-Human Trial Expected to Launch in '17

Financial news for TGTX dated on 2017-03-19: Don't Let Offerings Blindside Your Thesis

Financial news for TGTX dated on 2017-03-10: TG Therapeutics Reports Q4 EPS \$(0.48) vs. \$(0.36) Est., Sales \$38K vs. \$30K Est.

Financial news for TGTX dated on 2017-03-09: TG Therapeutics Prices Offering of ~5.128M Shares at \$9.75/Share

Financial news for TGTX dated on 2017-03-08: TG Therapeutics Reports Offering of Common Shares, No Terms Disclosed

Financial news for TGTX dated on 2017-03-07: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TGTX dated on 2017-03-07: H.C. Wainwright Reiterates Buy On TG Therapeutics, Maintains \$18 Price Target

Financial news for TGTX dated on 2017-03-06: Mid-Afternoon Market Update: GoPro Slides Following Goldman Sachs Downgrade; TG Therapeutics Shares Spike Higher

Financial news for TGTX dated on 2017-03-06: SunTrust Comments on TG Therapeutics Following Phase 3 GENUINE Study Results: Sees Approval for TG-1101, Raises Price Target to \$26

Financial news for TGTX dated on 2017-03-06: 15 Biggest Mid-Day Gainers For Monday

Financial news for TGTX dated on 2017-03-06: Mid-Day Market Update: Dow Falls 80 Points; Concert Pharma Shares Spike Higher

Financial news for TGTX dated on 2017-03-06: Hearing FBR Raises Price Target For TG Therapeutics To \$26/Share

Financial news for TGTX dated on 2017-03-06: Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital

Financial news for TGTX dated on 2017-03-06: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for TGTIX dated on 2017-03-06: TGTIX Resumes Trade, Up Over 30.8% After Hours At \$8.70

Financial news for TGTIX dated on 2017-03-06: TG Therapeutics to Resume Trading at 7:30 AM ET

Financial news for TGTIX dated on 2017-03-06: UPDATE: TG Therapeutics Says GENUINE Study Of TG-1101 Was Well Tolerated With Consistent Safety Profile With Phase 2 Study Of ublituximab Plus ibrutinib

Financial news for TGTIX dated on 2017-03-06: TG Therapeutics Phase 3 GENUINE Study Meets Primary Endpoint

Financial news for TGTIX dated on 2017-03-06: TG Therapeutics and Concert Pharma Halted

Financial news for TGTIX dated on 2017-02-22: Aegis Capital Initiates Coverage On TG Therapeutics at Buy, Announces \$26.00 Target

Financial news for TGTIX dated on 2017-01-24: TG Therapeutics Reports orphan Drug Designation for Combo of TG-1101, TGR-1202 for Treatment of Diffuse Large B-cell Lymphoma

Financial news for TGTIX dated on 2017-01-11: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for TGTIX dated on 2017-01-11: TG Therapeutics Surrenders Early Gains After Positive Multiple Sclerosis Study Data

Financial news for TGTIX dated on 2017-01-11: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TGTIX dated on 2017-01-11: TG Therapeutics +18% Premarket @\$5.90; Co Announced Positive MS Study Data

Financial news for TGTIX dated on 2017-01-09: TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 in Treatment of Chronic Lymphocytic Leukemia

Financial news for TGTIX dated on 2017-01-04: TG Therapeutics Investigator Initiated Study of TGR-1202

Financial news for TGTIX dated on 2016-12-16: TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 2 Trial of TG-1101

Financial news for TGTIX dated on 2016-12-06: TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment, Top-Line Data Expected First Half 2017

Financial news for TGTIX dated on 2016-12-05: TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib in Patients with Relapsed, Refractory CLL, MCL Showed Combo is Well Tolerated with No Grade 3/4 Transaminitis, Pneumonitis, Diarrhea, Colitis Observed

Financial news for TGTIX dated on 2016-11-22: TG Therapeutics Up 2.5+% PreMarket; Earlier Announced Positive DSMB Recommendation for Continuation of Unity-CLL Phase 3 Trial

Financial news for TGTIX dated on 2016-11-07: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for TGTIX dated on 2016-11-07: TG Therapeutics Reports Q3 Net Loss \$24.8M vs \$13.7M in Same Qtr. Last Year, EPS \$(0.50) vs \$(0.31) Est.

Financial news for TGTIX dated on 2016-10-27: TG Therapeutics, Inc. Reports Publication in Blood Describing a Novel Complimentary Mechanism of the PI3K-delta Inhibitor, TGR-1202

Financial news for TGTIX dated on 2016-10-14: Ladenburg Thalmann Positive On TG Therapeutics Post Adjustments To GENUINE Study

Financial news for TGTIX dated on 2016-10-14: TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track

Financial news for TGTIX dated on 2016-10-13: 15 Biggest Mid-Day Losers For Thursday

Financial news for TGTIX dated on 2016-10-13: Mid-Morning Market Update: Markets Open Lower; Delta Air Lines Profit Beats Estimates

Financial news for TGTIX dated on 2016-10-13: 18 Stocks Moving In Thursday's Pre-

Market Session

Financial news for TGTX dated on 2016-10-13: TG Therapeutics, Inc. Amends the GENUINE Phase 3 Clinical Trial, Revising Primary Endpoint to Overall Response Rate

Financial news for TGTX dated on 2016-10-06: TG Therapeutics Has Quite The Promising Pipeline

Financial news for TGTX dated on 2016-10-06: Brean Capital Assumes TG Therapeutics at Buy, Announces \$28.00 PT

Financial news for TGTX dated on 2016-08-26: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder

Financial news for TGTX dated on 2016-08-24: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for TGTX dated on 2016-08-24: TG Therapeutics Reports Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia

Financial news for TGTX dated on 2016-08-08: A Handful of Biotech Stocks Plunge After Disappointing Results

Financial news for TGTX dated on 2016-08-08: 12 Biggest Mid-Day Losers For Monday

Financial news for TGTX dated on 2016-08-08: TG Therapeutics Reports Q2 EPS \$(0.33) vs. Est. \$(0.29)

Financial news for TGTX dated on 2016-07-18: Stocks Hitting 52-Week Lows

Financial news for TGTX dated on 2016-06-10: TG Therapeutics Reports TGR-1202 in Combo with Ibrutinib, Recaps Long-Term Safety, Efficacy Data of TGR-1202 in CLL, NHLs

Financial news for TGTX dated on 2016-06-07: TG Therapeutics Reports First Patient Enrolled in Registration-Directed UNITY-DLBCL Phase 2b Trial

Financial news for TGTX dated on 2016-06-06: TG Therapeutics Reports TGR-1202 Shows High Response Rates And Differentiated & Favorable Safety Profile

Financial news for TGTX dated on 2016-05-27: Benzinga's Top Initiations

Financial news for TGTX dated on 2016-05-27: TG Therapeutics Strikes Global Alliance To Develop Novel BET Inhibitors For Hematological Malignancies Treatment

Financial news for TGTX dated on 2016-05-27: The Market In 5 Minutes: Happy Memorial Day Weekend

Financial news for TGTX dated on 2016-05-27: TG Therapeutics Enters Global Partnership To Develop, Commercialize Novel BET Inhibitors Developed By Jubilant Biosys For Hematological Malignancy Treatments; Receives Upfront Licensing Fee Of \$1M & Potential Milestones Of ~\$177M

Financial news for TGTX dated on 2016-05-27: SunTrust Robinson Humphrey Initiates Coverage on TG Therapeutics at Buy

Financial news for TGTX dated on 2016-05-10: TG Therapeutics Reports Q1 EPS \$(0.28) vs \$(0.36) Est., License Sales \$38.1K vs \$30K Est.

Financial news for TGTX dated on 2016-05-03: TG Therapeutics Reports Launch of First Clinical Trial in MS for TG-1101

Financial news for TGTX dated on 2016-04-18: TG Therapeutics To Present Pre-Clinical Data At American Association For Cancer Research Annual Meeting

Financial news for TGTX dated on 2016-04-13: TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States

Financial news for TGTX dated on 2016-03-17: TG Therapeutics, Inc. Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research Meeting

Financial news for TGTX dated on 2016-03-07: TG Therapeutics Plans Launch of First Phase 2 Trial In MS for TG-1101 Next 30-60 Days

Financial news for TGTX dated on 2016-03-07: TG Therapeutics Reports Q4 EPS \$(0.37) Vs Est \$(0.32), Sales \$38.095K Vs Est \$40.0K

Financial news for TGTX dated on 2016-01-24: Jim Cramer Dishes On Microsoft, Gilead, TG Therapeutics & NY Community Bancorp

Financial news for TGTX dated on 2016-01-12: TG Therapeutics +11.46% @\$8.85; Co Presenting at J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 9:00 PST

Financial news for TGTX dated on 2015-12-07: Roth Capital Reiterates Buy & 'Focus List' Status On TG Therapeutics, Sees Co. 'positioning itself strongly'

Financial news for TGTX dated on 2015-12-07: TG Therapeutics, Inc. Announces Oral Presentation of Novel Pre-Clinical Combinations With TGR-1202 by Investigators at Columbia University

Financial news for TGTX dated on 2015-12-06: TG Therapeutics Announces Data Presentations from Ongoing Clinical Studies in Patients With NHL, CLL at #ASH2015

Financial news for TGTX dated on 2015-12-01: FBR Capital Earlier Initiated Coverage on TG Therapeutics at Outperform, Announced \$29.00 PT

Financial news for TGTX dated on 2015-11-09: TG Therapeutics Reports Q3 EPS \$(0.28) vs. Est. \$(0.34), Rev. \$38.096K vs. Est. \$40K

Financial news for TGTX dated on 2015-10-05: 13G Filing from Bridger Mgmt on TG Therapeutics Shows New 6% Stake

Financial news for TGTX dated on 2015-09-17: Mid-Morning Market Update: Markets Mostly Flat; Rite Aid Earnings Miss Views

Financial news for TGTX dated on 2015-09-17: Morning Market Gainers

Financial news for TGTX dated on 2015-09-17: TG Therapeutics Announces Special Protocol Assessment Agreement With the FDA for the First Phase 3 Clinical Trial of Its Proprietary Combination Regimen of TG-1101 in Combination With TGR-1202 for Patients With Chronic Lymphocytic Leukemia

Financial news for TGTX dated on 2015-09-09: TG Therapeutics, Inc. Launches Phase 1/2 "Triple-Therapy" Study With TGR-1202 + TG-1101 + the PD-1 Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Chronic Lymphocytic Leukemia (CLL) at the University of Pennsylvania's Abramson Cancer Center

Financial news for TGTX dated on 2015-08-12: TG Therapeutics: A Buy Worth \$22

Financial news for TGTX dated on 2015-08-12: H.C. Wainwright Assumes TG Therapeutics at Buy, Announces \$22.00 PT

Financial news for TGTX dated on 2015-08-10: TG THERapeutics Reports Q2 Loss \$0.38 Vs Est Loss \$0.30

Financial news for TGTX dated on 2015-06-18: New Results From Phase 2 Clinical Trial of TG-1101 in Combination With Ibrutinib Confirms Robust Clinical Activity With a Favorable Safety in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia

Financial news for TGTX dated on 2015-06-11: TG Therapeutics to Present Clinical Data on TG-1101 and TGR-1202 at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma

Financial news for TGTX dated on 2015-06-04: Tedegar Increase Dividend To \$0.11 From \$0.09

Financial news for TGTX dated on 2015-06-03: What's Happening At The ASCO Conference?

Financial news for TGTX dated on 2015-06-01: TG Therapeutics Announces the Triple Combination of TG-1101, TGR-1202 and Ibrutinib is Safe and Highly Active in Patients With Advanced B-Cell Malignancies

Financial news for TGTX dated on 2015-05-31: TG Therapeutics Presents Proprietary Combination of TG-1101 Plus TGR-1202 as Well as TGR-1202 as a Single Agent in Ongoing Phase I/Ib Dose Escalation Clinical Studies

Financial news for TGTX dated on 2015-05-04: TG Therapeutics Reports Q1 GAAP Loss of \$0.39/Share, May Not Compare to Loss of \$0.33/Share

Financial news for TGTX dated on 2015-05-04: TG Therapeutics Reports Q1 EPS Loss \$0.36 Vs Est Loss \$0.33

Financial news for TGTX dated on 2015-04-20: Ligand Announces Partner TG Therapeutics Shows Positive Pre-Clinical Data on IRAK4 Compounds

Financial news for TGTX dated on 2015-04-20: TG Therapeutics, Inc. Presents Pre-

clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting

Financial news for TGTX dated on 2015-03-11: TG Therapeutics Reports Q4 EPS \$(0.48) vs. Est. \$(0.26)

Financial news for TGTX dated on 2015-03-04: TG Therapeutics Reports Global Collaboration with Checkpoint Therapeutics for Development, Commercialization of Novel Immuno-Oncology Targeted Antibodies

Financial news for TGTX dated on 2015-03-04: Coronado Biosciences Forms Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies

Financial news for TGTX dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for TGTX dated on 2015-01-05: TG Therapeutics Shares Spike to High

Financial news for TGTX dated on 2014-12-29: The Top 5 Biotech Gainers Of 2014

Financial news for TGTX dated on 2014-12-09: TG Therapeutics Announces Preliminary Results From Ongoing Phase I/II Dose Escalation Study of TG-1101

Financial news for TGTX dated on 2014-12-08: TG Therapeutics Reports Data from Phase 2 Trial of TG-1101, Ibrutinib Show 'Compelling Clinical Activity in Patients with Previously Treated, High-Risk CLL

Financial news for TGTX dated on 2014-12-01: TG Therapeutics Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib For Patients With Select B-Cell Malignancies

Financial news for TGTX dated on 2014-10-27: Wainwright Sees TG Therapeutics As Take-Out Target

Financial news for TGTX dated on 2014-10-27: UPDATE: H.C. Wainwright Initiates Coverage On TG Therapeutics On Significant Long-Term Upside

Financial news for TGTX dated on 2014-10-27: H.C. Wainwright Initiates Coverage on TG THERAPEUTICS INC at Buy, Announces \$17.00 PT

Financial news for TGTX dated on 2014-10-17: 13G Filing from RA Capital Mgmt on TG Therapeutics Shows New 8.3% Stake

Financial news for TGTX dated on 2014-09-23: TG Therapeutics Announces Exercise of License Option For Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202

Financial news for TGTX dated on 2014-09-15: US Stock Futures Down Ahead Of Industrial Production Report

Financial news for TGTX dated on 2014-09-15: TG Therapeutics Announces Special Protocol Assessment Agreement With The FDA for Its First Phase 3 Clinical Trial of TG-1101 In Combination With Imbruvica[®] for Patients With Previously Treated Chronic Lymphocytic Leukemia

Financial news for TGTX dated on 2014-08-15: TG Therapeutics Reports Novel 'Chemo-Free' Triple Therapy Combo Study for Patients with Chronic Lymphocytic Leukemia, Other B-Cell Malignancies

Financial news for TGTX dated on 2014-08-07: TG Therapeutics Spikes to High on Volume

Financial news for TGTX dated on 2014-07-21: TG Therapeutics' Novel Combination of TG-1101 and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas

Financial news for TGTX dated on 2014-07-21: TG THERAPEUTICS INC Reports Q4 EPS of \$(0.36) vs \$(0.24) Est

Financial news for TGTX dated on 2014-07-02: UPDATE: MLV & Co. Reiterates On TG Therapeutics On Multiple Positive Factors

Financial news for TGTX dated on 2014-06-24: Benzinga's Volume Movers

Financial news for TGTX dated on 2014-06-24: TG Therapeutics Completes Licensing Agreement With Ligand Pharma to Develop Inhibitors of IRAK4

Financial news for TGTX dated on 2014-06-24: Ligand Signs License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program

Financial news for TGTX dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for TGTX dated on 2014-06-13: Morning Market Losers

Financial news for TGTX dated on 2014-06-13: US Stock Futures Fall Ahead Of Consumer Sentiment Report

Financial news for TGTX dated on 2014-06-13: TG Therapeutics' TG-1101 in Combination With Ibrutinib Shows 90% Response Rate in Patients With Previously Treated CLL and MCL

Financial news for TGTX dated on 2014-06-12: Mid-Day Market Movers For Thursday, June 12, 2014

Financial news for TGTX dated on 2014-05-30: TG Therapeutics Announces Will Present Highlighted Data from TGR-1202 Data

Financial news for TGTX dated on 2014-05-12: TG THERAPEUTICS INC Reports Q1 EPS of \$(0.25) vs \$(0.19) Est; Reaffirms Outlook

Financial news for TGTX dated on 2014-05-08: TG Therapeutics Provides Update on a Modified TGR-1202 Formulation and Fed-State Dosing With Data Demonstrating Significantly Higher TGR-1202 Exposure

Financial news for TGTX dated on 2014-03-11: TG Therapeutics Reports Sale of 2.7M Shares at \$6.71/Share

Financial news for TGTX dated on 2014-03-05: TG THERAPEUTICS INC Reports Q4 EPS of \$(0.19) vs \$(0.18) Est

Financial news for TGTX dated on 2013-12-09: TG Therapeutics Says TGR-1202 Appears Well Tolerated, Grade 3 Events Have Been Limited

Financial news for TGTX dated on 2013-12-09: TG Therapeutics Presents Encouraging TGR-1202 Data at ASH

Financial news for TGTX dated on 2013-11-25: TG Therapeutics Target Boosted from \$8 to \$12 at Ladenburg Thalmann

Financial news for TGTX dated on 2013-11-11: TG THERAPEUTICS INC Reports Q3 EPS of \$(0.16) vs \$(0.22) Est

Financial news for TGTX dated on 2013-11-06: Benzinga's Top Initiations

Financial news for TGTX dated on 2013-11-05: MLV & Co. Initiates Coverage on TG THERAPEUTICS INC at Buy, Announces \$9.00 PT

Financial news for TGTX dated on 2013-09-09: TG Therapeutics' Ublituximab Wins Orphan Drug Status for Treatment of NMZL, EMZL

Financial news for TGTX dated on 2013-09-06: Shares of TG Therapeutics Move Up 3% Following Added Orphan Drug Status from FDA

Financial news for TGTX dated on 2013-07-18: TG Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock Of 5.7 Million Shares At \$6.15 per Share

Financial news for TGTX dated on 2013-05-28: TG Therapeutics Approved for Listing on the NASDAQ Capital Market

Financial news for TGTX dated on 2012-11-08: Benzinga's Microcap Movers for Thursday November 8, 2012